Key Takeaways
- • Congressional Democrats introduced the "Stop Corporate Takeovers of Physicians Act of 2026" (S. 5419), which would establish a nationwide prohibition on many corporate practice of medicine arrangements, aimed largely at private equity.
- • The bill bars entities not majority-owned and controlled by licensed healthcare professionals from owning or controlling medical practices or employing covered clinicians, threatening common management services organization (MSO) structures.
- • Enforcement is broad: FTC investigative authority, state attorney general and private rights of action, treble damages, divestiture, disgorgement, and exclusion from federal healthcare programs.
- • A survey of 1,200 physicians found 78% believe PE investment could compromise patient care, while 61% said it could positively affect care through financial support.
- • Oregon has enacted similar legislation, and Connecticut, Illinois, Massachusetts, New Mexico, Vermont, and Washington are pursuing related state-level restrictions.
Summary
A coalition of congressional Democrats has introduced the "Stop Corporate Takeovers of Physicians Act of 2026" (S. 5419), legislation that could significantly reshape physician practice management across the United States. According to Senator John Markey (D-Mass.), "corporate greed is running rampant in every industry, but it is especially dangerous in healthcare." The bill restricts both actual and de facto ownership of many healthcare entities, particularly through management services organizations (MSOs). Its cornerstone prohibits any entity that is not majority-owned and controlled by licensed healthcare professionals from owning or controlling a medical practice or employing physicians, nurse practitioners, physician assistants, or other covered clinicians.
The bill would bar MSOs owned by private equity firms from controlling ownership transfers, financing acquisitions, owning practice interests, setting physician compensation, determining staffing, establishing productivity or revenue targets, controlling billing, directing payer contracting, influencing diagnostic coding, or exercising de facto operational control. It also prohibits non-clinicians from controlling patient admissions, clinical documentation, referrals, coding, and discharge planning, makes non-compete agreements with physicians unlawful and void, and bars MSOs from advertising for, hiring, or staffing medical practices.
Enforcement provisions are equally broad. Violations would constitute unfair or deceptive practices under consumer protection law, with the FTC gaining investigative authority over for-profit and certain nonprofit healthcare entities. State attorneys general could seek monetary and equitable relief, and private plaintiffs could sue. Courts could order divestiture and disgorgement, award treble damages, attorneys' fees, and costs, and violators could be excluded from federal healthcare programs.
The debate over private equity in medicine remains unsettled. A survey of 1,200 physicians found 61% said PE investment could positively affect patient care through financial support, while 78% said it could compromise care, and 82% felt it may encourage over-testing or overtreatment for profit. Proponents of PE investment note that practices need capital to counter declining reimbursement, fund staffing and equipment, and gain scale and negotiating leverage with insurers. Physician Mark Rieger, M.D., argued that legislation should preserve clinical autonomy while improving physicians' access to professional management and financing, and warned that the bill may fail.
At the state level, Oregon has enacted legislation resembling the federal proposal. Connecticut is weighing restrictions on private equity control of hospitals and expanded MSO oversight, Illinois is considering enhanced pre-merger notice requirements for PE and hedge fund transactions, and Massachusetts, New Mexico, Vermont, and Washington have pursued expanded attorney general review of healthcare transactions. Commentators note the federal bill may face Tenth Amendment challenges, potentially making state laws critical. The authors, Douglas Nadjari and Chaya Rosenbaum of Ruskin Moscou Faltischek P.C., also observe that New York's existing corporate practice prohibitions have weak enforcement, and that PE firms could redirect capital to less regulated sectors if restrictions tighten.
The bill would bar MSOs owned by private equity firms from controlling ownership transfers, financing acquisitions, owning practice interests, setting physician compensation, determining staffing, establishing productivity or revenue targets, controlling billing, directing payer contracting, influencing diagnostic coding, or exercising de facto operational control. It also prohibits non-clinicians from controlling patient admissions, clinical documentation, referrals, coding, and discharge planning, makes non-compete agreements with physicians unlawful and void, and bars MSOs from advertising for, hiring, or staffing medical practices.
Enforcement provisions are equally broad. Violations would constitute unfair or deceptive practices under consumer protection law, with the FTC gaining investigative authority over for-profit and certain nonprofit healthcare entities. State attorneys general could seek monetary and equitable relief, and private plaintiffs could sue. Courts could order divestiture and disgorgement, award treble damages, attorneys' fees, and costs, and violators could be excluded from federal healthcare programs.
The debate over private equity in medicine remains unsettled. A survey of 1,200 physicians found 61% said PE investment could positively affect patient care through financial support, while 78% said it could compromise care, and 82% felt it may encourage over-testing or overtreatment for profit. Proponents of PE investment note that practices need capital to counter declining reimbursement, fund staffing and equipment, and gain scale and negotiating leverage with insurers. Physician Mark Rieger, M.D., argued that legislation should preserve clinical autonomy while improving physicians' access to professional management and financing, and warned that the bill may fail.
At the state level, Oregon has enacted legislation resembling the federal proposal. Connecticut is weighing restrictions on private equity control of hospitals and expanded MSO oversight, Illinois is considering enhanced pre-merger notice requirements for PE and hedge fund transactions, and Massachusetts, New Mexico, Vermont, and Washington have pursued expanded attorney general review of healthcare transactions. Commentators note the federal bill may face Tenth Amendment challenges, potentially making state laws critical. The authors, Douglas Nadjari and Chaya Rosenbaum of Ruskin Moscou Faltischek P.C., also observe that New York's existing corporate practice prohibitions have weak enforcement, and that PE firms could redirect capital to less regulated sectors if restrictions tighten.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.